source
- FDA expands Anktiva use for BCG-unresponsive high-grade papillary bladder cancerThe U.S. Food and Drug Administration has broadened the approved use of Anktiva, a therapy given with Bacillus Calmette-Guérin, to treat adults with high-grade papillary-only bladder cancer that ha…
- FDA launches Rare Disease Framework Initiative to reshape drug development for small patient populationsThe FDA announced a new Rare Disease Framework Initiative aimed at overhauling how drugs and biologics for rare conditions are developed. The initiative will produce a tailored framework that refl…